基于氧化吲哚支架的含Src同源2结构域蛋白酪氨酸磷酸酶2（Shp2）抑制剂。
Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds.
作者信息
Lawrence Harshani R, Pireddu Roberta, Chen Liwei, Luo Yunting, Sung Shen-Shu, Szymanski Ann Marie, Yip M L Richard, Guida Wayne C, Sebti Saïd M, Wu Jie, Lawrence Nicholas J
机构信息
Drug Discovery Program, Moffitt Cancer Center, 12901 Magnolia Drive, Tampa, Florida 33612, USA.
出版信息
J Med Chem. 2008 Aug 28;51(16):4948-56. doi: 10.1021/jm8002526. Epub 2008 Aug 5.
Abstract
Screening of the NCI diversity set of compounds has led to the identification of 5 (NSC-117199), which inhibits the protein tyrosine phosphatase (PTP) Shp2 with an IC50 of 47 microM. A focused library incorporating an isatin scaffold was designed and evaluated for inhibition of Shp2 and Shp1 PTP activities. Several compounds were identified that selectively inhibit Shp2 over Shp1 and PTP1B with low to submicromolar activity. A model for the binding of the active compounds is proposed.
摘要
对美国国立癌症研究所（NCI）化合物多样性集进行筛选后，已鉴定出5种化合物（NSC - 117199），其对蛋白酪氨酸磷酸酶（PTP）Shp2具有抑制作用，半数抑制浓度（IC50）为47微摩尔。设计并评估了一个包含异吲哚酮支架的聚焦文库对Shp2和Shp1 PTP活性的抑制作用。鉴定出了几种化合物，它们对Shp2的选择性抑制作用优于Shp1和蛋白酪氨酸磷酸酶1B（PTP1B），活性低至亚微摩尔级。提出了活性化合物结合的模型。
相似文献
1
Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds.基于氧化吲哚支架的含Src同源2结构域蛋白酪氨酸磷酸酶2（Shp2）抑制剂。
J Med Chem. 2008 Aug 28;51(16):4948-56. doi: 10.1021/jm8002526. Epub 2008 Aug 5.
2
Benzo[c][1,2,5]thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.苯并[c][1,2,5]噻二唑衍生物：一类新型强效含Src同源2结构域蛋白酪氨酸磷酸酶2（SHP2）抑制剂。
Bioorg Med Chem Lett. 2017 Dec 1;27(23):5154-5157. doi: 10.1016/j.bmcl.2017.10.059. Epub 2017 Oct 26.
3
Synthesis and biological evaluation of heterocyclic bis-aryl amides as novel Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.杂环双芳酰胺类 Src 同源 2 结构域包含蛋白酪氨酸磷酸酶-2（SHP2）抑制剂的合成与生物评价。
Bioorg Med Chem Lett. 2020 Jun 1;30(11):127170. doi: 10.1016/j.bmcl.2020.127170. Epub 2020 Apr 3.
4
Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2.小肽化合物的合成、分子对接以及对蛋白酪氨酸磷酸酶1B（PTP1B）和含Src同源2结构域蛋白酪氨酸磷酸酶2（SHP2）的抑制活性评估。
Drug Des Devel Ther. 2018 Dec 5;12:4139-4147. doi: 10.2147/DDDT.S186614. eCollection 2018.
5
Polyphyllin D Shows Anticancer Effect through a Selective Inhibition of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP2).重楼苷 D 通过选择性抑制含Src 同源区 2 的蛋白酪氨酸磷酸酶-2（SHP2）发挥抗癌作用。
Molecules. 2021 Feb 5;26(4):848. doi: 10.3390/molecules26040848.
6
Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).用于致癌Src 同源物-2 结构域包含蛋白酪氨酸磷酸酶-2（SHP2）的水杨酸小分子抑制剂。
J Med Chem. 2010 Mar 25;53(6):2482-93. doi: 10.1021/jm901645u.
7
Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112.SPI-112的甲酯类似物对细胞Shp2活性的抑制作用。
Biochem Pharmacol. 2010 Sep 15;80(6):801-10. doi: 10.1016/j.bcp.2010.05.019. Epub 2010 May 25.
8
Decoding the selective mechanism behind a monobody inhibitor to the phosphatase domain of SHP2: insights from molecular dynamics simulations.解析单克隆抗体抑制剂作用于SHP2磷酸酶结构域背后的选择性机制：来自分子动力学模拟的见解
Phys Chem Chem Phys. 2025 Apr 30;27(17):9132-9142. doi: 10.1039/d5cp00211g.
9
Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors.合成和生物评价 2,5-二芳基-1,3,4-噁二唑衍生物作为新型Src 同源 2 结构域含蛋白酪氨酸磷酸酶 2（SHP2）抑制剂。
Bioorg Chem. 2021 Nov;116:105384. doi: 10.1016/j.bioorg.2021.105384. Epub 2021 Sep 23.
10
Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting Its Protein-Protein Interactions.靶向致癌性Src 同源性 2 结构域包含磷酸酶 2（SHP2），抑制其蛋白-蛋白相互作用。
J Med Chem. 2021 Nov 11;64(21):15973-15990. doi: 10.1021/acs.jmedchem.1c01371. Epub 2021 Oct 29.
引用本文的文献
1
Multicatalysis-Enabled Multicomponent Reactions Generate a PTP1B Inhibitor.多催化介导的多组分反应生成一种蛋白酪氨酸磷酸酶1B（PTP1B）抑制剂。
ACS Cent Sci. 2025 May 19;11(6):938-949. doi: 10.1021/acscentsci.5c00041. eCollection 2025 Jun 25.
2
Targeting Shp2 as a therapeutic strategy for neurodegenerative diseases.将靶向Shp2作为神经退行性疾病的治疗策略。
Transl Psychiatry. 2025 Jan 10;15(1):6. doi: 10.1038/s41398-024-03222-1.
3
Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor.发现TK-642是一种高效、选择性、口服生物可利用的基于吡唑并吡嗪的变构SHP2抑制剂。
Acta Pharm Sin B. 2024 Aug;14(8):3624-3642. doi: 10.1016/j.apsb.2024.03.028. Epub 2024 Mar 26.
4
Therapeutic potential of targeting protein tyrosine phosphatases in liver diseases.靶向蛋白酪氨酸磷酸酶在肝脏疾病中的治疗潜力
Acta Pharm Sin B. 2024 Aug;14(8):3295-3311. doi: 10.1016/j.apsb.2024.05.006. Epub 2024 May 13.
5
Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches.通过抑制SHP2克服癌症和免疫细胞中的免疫检查点治疗耐药性：文献综述与新型联合方法
Cancers (Basel). 2023 Nov 13;15(22):5384. doi: 10.3390/cancers15225384.
6
Development and validation of machine learning models for the prediction of SH-2 containing protein tyrosine phosphatase 2 inhibitors.用于预测 SH-2 含蛋白酪氨酸磷酸酶 2 抑制剂的机器学习模型的开发和验证。
Mol Divers. 2024 Aug;28(4):1889-1905. doi: 10.1007/s11030-023-10710-x. Epub 2023 Aug 8.
7
Exploring Allosteric Inhibitors of Protein Tyrosine Phosphatases Through High-Throughput Screening.通过高通量筛选探索蛋白酪氨酸磷酸酶的别构抑制剂。
Methods Mol Biol. 2023;2691:235-245. doi: 10.1007/978-1-0716-3331-1_18.
8
Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation.SHP2 磷酸酶结构域的单域抗体抑制剂及其作为定量检测 SHP2 变构调节探针的用途。
J Mol Biol. 2023 Apr 15;435(8):168010. doi: 10.1016/j.jmb.2023.168010. Epub 2023 Feb 16.
9
Toward a Treatment of Cancer: Design and In Vitro/In Vivo Evaluation of Uncharged Pyrazoline Derivatives as a Series of Novel SHP2 Inhibitors.针对癌症的治疗：作为一系列新型 SHP2 抑制剂的无电荷吡唑啉衍生物的设计及体外/体内评价。
Int J Mol Sci. 2022 Mar 23;23(7):3497. doi: 10.3390/ijms23073497.
10
Strategies to overcome drug resistance using SHP2 inhibitors.使用SHP2抑制剂克服耐药性的策略。
Acta Pharm Sin B. 2021 Dec;11(12):3908-3924. doi: 10.1016/j.apsb.2021.03.037. Epub 2021 Mar 28.
本文引用的文献
1
The tyrosine phosphatase Shp2 (PTPN11) in cancer.癌症中的酪氨酸磷酸酶Shp2（PTPN11）。
Cancer Metastasis Rev. 2008 Jun;27(2):179-92. doi: 10.1007/s10555-008-9126-y.
2
Targeting PTPs with small molecule inhibitors in cancer treatment.在癌症治疗中使用小分子抑制剂靶向蛋白酪氨酸磷酸酶。
Cancer Metastasis Rev. 2008 Jun;27(2):263-72. doi: 10.1007/s10555-008-9113-3.
3
The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway.Shp2在Ras/丝裂原活化蛋白激酶（ERK1/2）信号通路中的分子功能。
Cell Signal. 2008 Mar;20(3):453-9. doi: 10.1016/j.cellsig.2007.10.002. Epub 2007 Oct 11.
4
The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.Src同源2结构域酪氨酸磷酸酶SHP-1和SHP-2：对细胞生长、炎症和损伤的多样化调控
Histol Histopathol. 2007 Nov;22(11):1251-67. doi: 10.14670/HH-22.1251.
5
Strategies for developing protein tyrosine phosphatase inhibitors.开发蛋白酪氨酸磷酸酶抑制剂的策略。
Methods. 2007 Jul;42(3):250-60. doi: 10.1016/j.ymeth.2007.02.014.
6
Shp2, a novel oncogenic tyrosine phosphatase and potential therapeutic target for human leukemia.Shp2，一种新型致癌性酪氨酸磷酸酶，也是人类白血病潜在的治疗靶点。
Cell Res. 2007 Apr;17(4):295-7. doi: 10.1038/cr.2007.18.
7
The role of Shp2 (PTPN11) in cancer.Shp2（PTPN11）在癌症中的作用。
Curr Opin Genet Dev. 2007 Feb;17(1):23-30. doi: 10.1016/j.gde.2006.12.011. Epub 2007 Jan 16.
8
Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis.通过生物导向合成发现蛋白质磷酸酶抑制剂类别。
Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10606-11. doi: 10.1073/pnas.0601490103. Epub 2006 Jun 29.
9
Discovery of a novel shp2 protein tyrosine phosphatase inhibitor.一种新型Shp2蛋白酪氨酸磷酸酶抑制剂的发现。
Mol Pharmacol. 2006 Aug;70(2):562-70. doi: 10.1124/mol.106.025536. Epub 2006 May 22.
10
Stops along the RAS pathway in human genetic disease.人类遗传疾病中RAS信号通路的阻断点。
Nat Med. 2006 Mar;12(3):283-5. doi: 10.1038/nm0306-283.
Zotero 插件